Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors at 2026 American Society of Clinical Oncology Annual Meeting
Cogent Biosciences Announces FDA Acceptance of New Drug Application with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association 2026 Congress
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors at the 2026 American Society of Clinical Oncology Annual Meeting
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2026
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Bold Ventures Closes Acquisition of 6 Key Claims Contiguous to Its Joutel Property, Quebec and Completes IP Survey
Corcel Drills 56.65 Meters of 1.07% Cu, 0.79 g/t Au and 7.1 g/t Ag in the First Drill Hole at the Yuma King Project, Arizona
